CFTR Modulators ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	6

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05663255 (ClinicalTrials.gov)	March 1, 2023	15/12/2022	Effectiveness of CFTR Modulators According to Co-therapy	Is Effectiveness of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators Impacted by Co-therapy? A Population-based Comparative Effectiveness Study Using Data From French Cystic Fibrosis Registry Linked to French National Healthcare Insurance Database	Cystic Fibrosis	Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)	Hospices Civils de Lyon	NULL	Not yet recruiting	6 Years	N/A	All	1990		NULL
2	NCT05581056 (ClinicalTrials.gov)	February 24, 2023	12/10/2022	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTE Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTR Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation	Cystic Fibrosis	Drug: CFTR modulators	Hospices Civils de Lyon	NULL	Not yet recruiting	6 Years	11 Years	All	90		France
3	NCT04580368 (ClinicalTrials.gov)	May 1, 2021	2/10/2020	Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials	Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials	Cystic Fibrosis	Drug: CFTR Modulators	Children's Hospital Medical Center, Cincinnati	NULL	Recruiting	6 Years	N/A	All	50	N/A	United States
4	NCT04301856 (ClinicalTrials.gov)	January 1, 2020	21/2/2020	Response to CFTR Modulators in CF Patients Under 18 Years	Evaluation of the Response to CFTR Modulators in Patients With Cystic Fibrosis Less Than 18 Years of Age	Cystic Fibrosis in Children	Drug: CFTR Modulators	Societe Francaise de la Mucoviscidose	NULL	Recruiting	N/A	18 Years	All	600		France
5	NCT04206436 (ClinicalTrials.gov)	December 18, 2019	18/12/2019	CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis	CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis	Cystic Fibrosis;Bone Loss;Muscle Loss	Drug: Cftr Modulators	Indiana University	Cystic Fibrosis Foundation	Enrolling by invitation	18 Years	N/A	All	60		United States
6	NCT03506061 (ClinicalTrials.gov)	September 4, 2019	13/4/2018	Trikafta in Cystic Fibrosis Patients	iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations	Cystic Fibrosis	Drug: Trikafta	Emory University	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	12 Years	N/A	All	22	Phase 2	United States

Back to top